AAPL351.91-0.87 (-0.25%) ▼|ABBV292.82-1.73 (-0.59%) ▼|ABT104.71-2.74 (-2.55%) ▼|ACN239.28-8.42 (-3.40%) ▼|ADBE235.55-10.45 (-4.25%) ▼|AMAT349.23-1.02 (-0.29%) ▼|AMD503.41-0.87 (-0.17%) ▼|AMGN457.93-4.39 (-0.95%) ▼|AMT183.18-7.56 (-3.96%) ▼|AMZN257.89+0.14 (+0.05%) ▲|AVGO341.60+8.20 (+2.46%) ▲|AXP315.78-3.27 (-1.02%) ▼|BA163.91-1.31 (-0.79%) ▼|BAC49.44-0.64 (-1.28%) ▼|BKNG154.46-3.07 (-1.95%) ▼|BLK1,180.67-17.30 (-1.44%) ▼|BMY61.35-1.58 (-2.51%) ▼|BNY149.79-1.90 (-1.25%) ▼|BRK-B586.76-6.09 (-1.03%) ▼|C119.94-1.38 (-1.14%) ▼|CAT570.79+0.30 (+0.05%) ▲|CL99.61-1.38 (-1.37%) ▼|CMCSA25.31-0.29 (-1.13%) ▼|COF186.78-6.44 (-3.33%) ▼|COP139.48-1.04 (-0.74%) ▼|COST1,110.08-3.66 (-0.33%) ▼|CRM194.52-20.31 (-9.45%) ▼|CSCO95.11+0.59 (+0.62%) ▲|CVS85.81-2.78 (-3.14%) ▼|CVX216.13-1.01 (-0.47%) ▼|DE649.23-4.76 (-0.73%) ▼|DHR225.77-4.14 (-1.80%) ▼|DIS116.94-1.76 (-1.48%) ▼|DUK129.84-0.75 (-0.57%) ▼|EMR159.15-1.50 (-0.93%) ▼|FDX319.94-7.71 (-2.35%) ▼|GD355.63-4.06 (-1.13%) ▼|GE326.40+1.22 (+0.38%) ▲|GEV779.91+16.34 (+2.14%) ▲|GILD170.26+2.68 (+1.60%) ▲|GM84.05+0.44 (+0.52%) ▲|GOOG277.60-3.66 (-1.30%) ▼|GOOGL280.20-3.52 (-1.24%) ▼|GS877.52-14.02 (-1.57%) ▼|HD339.01-8.50 (-2.45%) ▼|HON218.96+1.01 (+0.46%) ▲|IBM231.09-11.42 (-4.71%) ▼|INTC55.17-0.27 (-0.49%) ▼|INTU320.79-24.77 (-7.17%) ▼|ISRG430.53-7.22 (-1.65%) ▼|JNJ278.70-3.85 (-1.36%) ▼|JPM329.96-8.25 (-2.44%) ▼|KO98.79-0.69 (-0.69%) ▼|LIN515.11-8.35 (-1.60%) ▼|LLY1,415.55-16.12 (-1.13%) ▼|LMT590.34+5.13 (+0.88%) ▲|LOW220.46-4.47 (-1.99%) ▼|LRCX210.69-0.14 (-0.07%) ▼|MA645.73-15.98 (-2.42%) ▼|MCD275.82+1.15 (+0.42%) ▲|MDLZ66.75-0.79 (-1.17%) ▼|MDT102.32-0.56 (-0.54%) ▼|META618.87-7.54 (-1.20%) ▼|MMM180.88-0.80 (-0.44%) ▼|MO77.46-1.44 (-1.83%) ▼|MRK143.37-1.09 (-0.75%) ▼|MS183.53-2.04 (-1.10%) ▼|MSFT506.24-11.75 (-2.27%) ▼|MU712.42-6.60 (-0.92%) ▼|NEE84.42-0.92 (-1.08%) ▼|NFLX59.68-1.07 (-1.76%) ▼|NKE35.85-2.41 (-6.30%) ▼|NOW92.90-6.47 (-6.51%) ▼|NVDA155.46-0.68 (-0.44%) ▼|ORCL115.00-4.09 (-3.43%) ▼|PEP142.02-4.41 (-3.01%) ▼|PFE28.47-0.39 (-1.35%) ▼|PG171.72-1.30 (-0.75%) ▼|PLTR156.56-3.83 (-2.39%) ▼|PM194.38-1.66 (-0.85%) ▼|QCOM166.67-1.85 (-1.10%) ▼|RTX198.00+3.11 (+1.60%) ▲|SBUX107.49-1.23 (-1.13%) ▼|SCHW91.84-1.10 (-1.18%) ▼|SO93.60-1.04 (-1.10%) ▼|SPG230.24-2.54 (-1.09%) ▼|T22.29-0.07 (-0.31%) ▼|TMO686.79-4.54 (-0.66%) ▼|TMUS167.90-2.11 (-1.24%) ▼|TSLA380.11+0.37 (+0.10%) ▲|TXN295.86+1.65 (+0.56%) ▲|UBER68.81-1.18 (-1.69%) ▼|UNH389.68-22.34 (-5.42%) ▼|UNP297.03-6.68 (-2.20%) ▼|UPS110.31-1.51 (-1.35%) ▼|USB59.18-1.25 (-2.07%) ▼|V416.77-9.69 (-2.27%) ▼|VZ45.93-0.41 (-0.88%) ▼|WFC82.69-2.15 (-2.53%) ▼|WMT127.52-0.89 (-0.69%) ▼|XOM167.21+0.34 (+0.20%) ▲|AAPL351.91-0.87 (-0.25%) ▼|ABBV292.82-1.73 (-0.59%) ▼|ABT104.71-2.74 (-2.55%) ▼|ACN239.28-8.42 (-3.40%) ▼|ADBE235.55-10.45 (-4.25%) ▼|AMAT349.23-1.02 (-0.29%) ▼|AMD503.41-0.87 (-0.17%) ▼|AMGN457.93-4.39 (-0.95%) ▼|AMT183.18-7.56 (-3.96%) ▼|AMZN257.89+0.14 (+0.05%) ▲|AVGO341.60+8.20 (+2.46%) ▲|AXP315.78-3.27 (-1.02%) ▼|BA163.91-1.31 (-0.79%) ▼|BAC49.44-0.64 (-1.28%) ▼|BKNG154.46-3.07 (-1.95%) ▼|BLK1,180.67-17.30 (-1.44%) ▼|BMY61.35-1.58 (-2.51%) ▼|BNY149.79-1.90 (-1.25%) ▼|BRK-B586.76-6.09 (-1.03%) ▼|C119.94-1.38 (-1.14%) ▼|CAT570.79+0.30 (+0.05%) ▲|CL99.61-1.38 (-1.37%) ▼|CMCSA25.31-0.29 (-1.13%) ▼|COF186.78-6.44 (-3.33%) ▼|COP139.48-1.04 (-0.74%) ▼|COST1,110.08-3.66 (-0.33%) ▼|CRM194.52-20.31 (-9.45%) ▼|CSCO95.11+0.59 (+0.62%) ▲|CVS85.81-2.78 (-3.14%) ▼|CVX216.13-1.01 (-0.47%) ▼|DE649.23-4.76 (-0.73%) ▼|DHR225.77-4.14 (-1.80%) ▼|DIS116.94-1.76 (-1.48%) ▼|DUK129.84-0.75 (-0.57%) ▼|EMR159.15-1.50 (-0.93%) ▼|FDX319.94-7.71 (-2.35%) ▼|GD355.63-4.06 (-1.13%) ▼|GE326.40+1.22 (+0.38%) ▲|GEV779.91+16.34 (+2.14%) ▲|GILD170.26+2.68 (+1.60%) ▲|GM84.05+0.44 (+0.52%) ▲|GOOG277.60-3.66 (-1.30%) ▼|GOOGL280.20-3.52 (-1.24%) ▼|GS877.52-14.02 (-1.57%) ▼|HD339.01-8.50 (-2.45%) ▼|HON218.96+1.01 (+0.46%) ▲|IBM231.09-11.42 (-4.71%) ▼|INTC55.17-0.27 (-0.49%) ▼|INTU320.79-24.77 (-7.17%) ▼|ISRG430.53-7.22 (-1.65%) ▼|JNJ278.70-3.85 (-1.36%) ▼|JPM329.96-8.25 (-2.44%) ▼|KO98.79-0.69 (-0.69%) ▼|LIN515.11-8.35 (-1.60%) ▼|LLY1,415.55-16.12 (-1.13%) ▼|LMT590.34+5.13 (+0.88%) ▲|LOW220.46-4.47 (-1.99%) ▼|LRCX210.69-0.14 (-0.07%) ▼|MA645.73-15.98 (-2.42%) ▼|MCD275.82+1.15 (+0.42%) ▲|MDLZ66.75-0.79 (-1.17%) ▼|MDT102.32-0.56 (-0.54%) ▼|META618.87-7.54 (-1.20%) ▼|MMM180.88-0.80 (-0.44%) ▼|MO77.46-1.44 (-1.83%) ▼|MRK143.37-1.09 (-0.75%) ▼|MS183.53-2.04 (-1.10%) ▼|MSFT506.24-11.75 (-2.27%) ▼|MU712.42-6.60 (-0.92%) ▼|NEE84.42-0.92 (-1.08%) ▼|NFLX59.68-1.07 (-1.76%) ▼|NKE35.85-2.41 (-6.30%) ▼|NOW92.90-6.47 (-6.51%) ▼|NVDA155.46-0.68 (-0.44%) ▼|ORCL115.00-4.09 (-3.43%) ▼|PEP142.02-4.41 (-3.01%) ▼|PFE28.47-0.39 (-1.35%) ▼|PG171.72-1.30 (-0.75%) ▼|PLTR156.56-3.83 (-2.39%) ▼|PM194.38-1.66 (-0.85%) ▼|QCOM166.67-1.85 (-1.10%) ▼|RTX198.00+3.11 (+1.60%) ▲|SBUX107.49-1.23 (-1.13%) ▼|SCHW91.84-1.10 (-1.18%) ▼|SO93.60-1.04 (-1.10%) ▼|SPG230.24-2.54 (-1.09%) ▼|T22.29-0.07 (-0.31%) ▼|TMO686.79-4.54 (-0.66%) ▼|TMUS167.90-2.11 (-1.24%) ▼|TSLA380.11+0.37 (+0.10%) ▲|TXN295.86+1.65 (+0.56%) ▲|UBER68.81-1.18 (-1.69%) ▼|UNH389.68-22.34 (-5.42%) ▼|UNP297.03-6.68 (-2.20%) ▼|UPS110.31-1.51 (-1.35%) ▼|USB59.18-1.25 (-2.07%) ▼|V416.77-9.69 (-2.27%) ▼|VZ45.93-0.41 (-0.88%) ▼|WFC82.69-2.15 (-2.53%) ▼|WMT127.52-0.89 (-0.69%) ▼|XOM167.21+0.34 (+0.20%) ▲|
13.7 C
New York
Wednesday, November 18, 2026

Tag: company

Ascletis Announces FDA IND Submission of ASC39, an Oral Small Molecule Selective Amylin Receptor Agonist for the Treatment of Obesity

- ASC39, an oral small molecule selective amylin receptor agonist, demonstrated eloralintide-like amylin selectivity and efficacy in preclinical models.- ASC39 demonstrated eloralintide-like selectivity for...

Antengene Presents Latest Clinical Results for ATG-022 and ATG-037 at ESMO 2026

SHANGHAI and HONG KONG, Oct. 26, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to...

2026 ESMO | Innovent Presents Multiple Clinical Data Updates for IBI363/TAK-928, a PD-1/Alpha-Biased IL-2 Bispecific Fusion Protein

The data showcased are from three Phase 1b clinical studies of IBI363/TAK-928 in first-line NSCLC, first-line G/GEJA, and immunotherapy-resistant lung adenocarcinoma, further supporting its...

Antengene Presents Latest Clinical Results for ATG-022 and ATG-037 at ESMO 2026

SHANGHAI and HONG KONG, Oct. 25, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to...

DiDi Shareholders Overwhelmingly Back Hong Kong Relisting; Want Independent Director, Open Earnings Calls, and First Shareholder Meeting in Four Years, Survey Finds

A Heng Ren Partners survey this month finds at least 99.3% support on five key shareholder issues to boost shareholder value; shareholders want DiDi's...

DiDi Shareholders Overwhelmingly Back Hong Kong Relisting; Want Independent Director, Open Earnings Calls, and First Shareholder Meeting in Four Years, Survey Finds

A Heng Ren Partners survey this month finds at least 99.3% support on five key shareholder issues to boost shareholder value; shareholders want DiDi's...

Clarins Lights Up the Austin Skyline with an Immersive Celebration of Skin Longevity

AUSTIN, Texas, Oct. 25, 2026 /PRNewswire/ -- French prestige beauty brand, Clarins, hosted an exclusive rooftop celebration in Austin, Texas, bringing together science, technology...

Drive to Great! BAIC FOTON Africa Partners Conference Set to Open

BEIJING, Oct. 25, 2026 /PRNewswire/ -- On October 29, the BAIC FOTON Africa Partners Conference, themed "Drive to Great," will be held in Port Elizabeth,...

The 31st MIF, 2026PLPEX & 2026MFE Conclude Successfully, Facilitating Cross-Sector Co-operation and Enhancing Investment Promotion through Exhibitions

MACAO, Oct. 25, 2026 /PRNewswire/ -- The 31st Macao International Trade & Investment Fair (31st MIF), the 2026 Portuguese Speaking Countries Products and Services...

Positive Overall Survival Results from the Phase III HARMONi-GI1 Trial of Ivonescimab Plus Chemotherapy Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer Presented...

HONG KONG, Oct. 25, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) today announced the presentation of results from the randomized, controlled, double-blind, multicenter, registrational Phase...

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer

Responses were deep and durable, with 65% ongoing at clinical cutoffResults support continued evaluation of the investigational RYBREVANT FASPRO regimen in the ongoing first-line Phase...

LexisNexis Coplogic Solutions Introduces Field Clarity for LexisNexis® Desk Officer Reporting System (DORS) at IACP 2026

A new, modern DORS and Field Clarity, the First AI-Guided Smartphone Video Assistant, Enhances Community Experience and Helps Improve Evidence, Case BuildingORLANDO, Fla., Oct....

Come Back to Firefox: Mozilla launches its most ambitious campaign yet to bring people back to the independent alternative to big tech browsers

As tracking and unwanted AI reshape the web, Firefox reunites the internet's original viral icons to make the case for a browser that puts...

Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO

Median OS was extended by 8.5 months compared with platinum-based doublet chemotherapy (25.9 vs 17.4 months), with a 31% reduction in the risk of...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCompany